- Home
- STTK vs SLQT Comparison
STTK vs SLQT Comparison
Compare STTK & SLQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STTK | SLQT |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.9M | 151.6M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STTK | SLQT |
|---|---|---|
| Price | $5.99 | $0.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $7.00 | $2.88 |
| AVG Volume (30 Days) | 574.2K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 53.02 | ★ 105.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | $1,000,000.00 | ★ $1,526,594,000.00 |
| Revenue This Year | N/A | $11.42 |
| Revenue Next Year | N/A | $7.76 |
| P/E Ratio | ★ N/A | $67.14 |
| Revenue Growth | N/A | ★ 15.50 |
| 52 Week Low | $0.69 | $0.65 |
| 52 Week High | $6.13 | $3.97 |
Technical Indicators
Market Signals| Indicator | STTK | SLQT |
|---|---|---|
| Relative Strength Index (RSI) | 72.78 | 24.43 |
| Support Level | $1.85 | N/A |
| Resistance Level | N/A | $0.94 |
| Average True Range (ATR) | 0.40 | 0.06 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 89.34 | 4.31 |
Price Performance
Historical ComparisonAbout STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About SLQT SelectQuote Inc.
SelectQuote Inc is a Direct-to-consumer (DTC) distribution platform which facilitates consumers to shop for health, life and auto & home insurance policies online. The company generates its revenues by selling insurance products on behalf of the insurance carrier partners in the form of a commission. It has four reportable segments namely Senior, Healthcare Services, Life, and Auto & Home. It functions through three lines namely, SelectQuote Senior, SelectQuote Life, and SelectQuote Auto & Home.